Stoke Therapeutics Chief Executive Edward Kaye Stepping Down

Dow Jones

03/18

By Colin Kellaher

Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company.

Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye.

The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search.

Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member.

The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 18, 2025 07:22 ET (11:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2520262466"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520262466\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520262466?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-18 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520262466","market":"other","top_or_hot":-1,"title":"Stoke Therapeutics Chief Executive Edward Kaye Stepping Down","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company. \n</p>\n<p>\n  Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye. \n</p>\n<p>\n  The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search. \n</p>\n<p>\n  Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member. \n</p>\n<p>\n  The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2025 07:22 ET (11:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stoke Therapeutics Chief Executive Edward Kaye Stepping Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStoke Therapeutics Chief Executive Edward Kaye Stepping Down\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-03-18 19:22</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company. \n</p>\n<p>\n  Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye. \n</p>\n<p>\n  The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search. \n</p>\n<p>\n  Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member. \n</p>\n<p>\n  The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2025 07:22 ET (11:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520262466","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520262466","pubTimestamp":1742296920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company.Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye.The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search.Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member.The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","STOK":"Stoke Therapeutics, Inc."},"translate_title":"Stoke Therapeutics首席执行官爱德华·凯辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STOK":0.9,"LENZ":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company. \n\n\n  Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye. \n\n\n  The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search. \n\n\n  Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member. \n\n\n  The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 07:22 ET (11:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}